Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients.

[1]  J. Heemskerk.  More than reverting tyrosine kinases. , 2022, Blood.

[2]  A. Sickmann,et al.  Roles of Focal Adhesion Kinase PTK2 and Integrin αIIbβ3 Signaling in Collagen- and GPVI-Dependent Thrombus Formation under Shear , 2022, International journal of molecular sciences.

[3]  A. Greinacher,et al.  GPVI expression is linked to platelet size, age, and reactivity , 2022, Blood advances.

[4]  Jiao Kong,et al.  Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors. , 2022, RSC medicinal chemistry.

[5]  Shu Wang,et al.  Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy. , 2022, Journal of medicinal chemistry.

[6]  M. Nijziel,et al.  Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function , 2021, EJHaem.

[7]  G. Shapiro,et al.  Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors. , 2021 .

[8]  M. Peppelenbosch,et al.  The role of phospho-tyrosine signaling in platelet biology and hemostasis. , 2020, Biochimica et biophysica acta. Molecular cell research.

[9]  P. Hammerman,et al.  Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling , 2020, Clinical Cancer Research.

[10]  Michael K. Wendt,et al.  SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer , 2020, Oncogene.

[11]  Runling Wang,et al.  Allosteric inhibitors of SHP2: an updated patent review (2015-2020). , 2020, Current medicinal chemistry.

[12]  Xiao-Feng Xiong,et al.  Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies , 2020, Acta pharmaceutica Sinica. B.

[13]  R. van Oerle,et al.  Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation , 2020, Scientific Reports.

[14]  S. Nampoothiri,et al.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations , 2020, BMC Medical Genetics.

[15]  Haopeng Sun,et al.  Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. , 2020, European journal of medicinal chemistry.

[16]  B. Neel,et al.  Catalytic dysregulation of SHP2 leading to Noonan syndromes impacts on platelet signaling and functions. , 2019, Blood.

[17]  Qiang Xu,et al.  Targeting SHP2 as a promising strategy for cancer immunotherapy. , 2019, Pharmacological research.

[18]  M. Loza,et al.  A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade , 2019, Thrombosis and Haemostasis.

[19]  Y. Liu,et al.  Platelet Shp2 negatively regulates thrombus stability under high shear stress , 2018, Journal of thrombosis and haemostasis : JTH.

[20]  W. Ouwehand,et al.  High-throughput elucidation of thrombus formation reveals sources of platelet function variability , 2018, Haematologica.

[21]  Qiang Xu,et al.  Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis , 2017, Nature Communications.

[22]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[23]  S. Pfister,et al.  Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk , 2017, Clinical Cancer Research.

[24]  Sarah L. Williams,et al.  Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. , 2016, Journal of medicinal chemistry.

[25]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[26]  J. Heemskerk,et al.  Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Summar,et al.  Malignancy in Noonan syndrome and related disorders , 2015, Clinical genetics.

[28]  S. Rahmouni,et al.  Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy. , 2015, Bioorganic & medicinal chemistry.

[29]  Rachel Cavill,et al.  Identification of platelet function defects by multi-parameter assessment of thrombus formation , 2014, Nature Communications.

[30]  I. Martinelli,et al.  Hemostatic Abnormalities in Noonan Syndrome , 2014, Pediatrics.

[31]  H. ten Cate,et al.  Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry , 2013, Thrombosis and Haemostasis.

[32]  B. Neel,et al.  Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. , 2013, Blood.

[33]  S. Watson,et al.  Mice Lacking the ITIM-Containing Receptor G6b-B Exhibit Macrothrombocytopenia and Aberrant Platelet Function , 2012, Science Signaling.

[34]  L. Kiemeney,et al.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation , 2011, European Journal of Human Genetics.

[35]  D. Jackson,et al.  CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. , 2009, Blood.

[36]  Y. Matsubara,et al.  The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders , 2008, Human mutation.

[37]  I. van der Burgt,et al.  Noonan Syndrome , 2019, Encyclopedia of Endocrine Diseases.

[38]  R. Foà,et al.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.

[39]  M. V. van Zandvoort,et al.  The Glycoprotein VI-Phospholipase C&ggr;2 Signaling Pathway Controls Thrombus Formation Induced by Collagen and Tissue Factor In Vitro and In Vivo , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Krieger,et al.  Neurofibromatosis–Noonan syndrome: Molecular evidence of the concurrence of both disorders in a patient , 2005, American journal of medical genetics. Part A.

[41]  H. Ohashi,et al.  Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia , 2005, Journal of Human Genetics.

[42]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[43]  B. Gelb,et al.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.

[44]  S. Watson,et al.  GPVI levels in platelets: relationship to platelet function at high shear. , 2003, Blood.

[45]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[46]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[47]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[48]  T. Pawson,et al.  Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp‐2 , 1997, The EMBO journal.

[49]  E. Mariman,et al.  Clinical and molecular studies in a large Dutch family with Noonan syndrome. , 1994, American journal of medical genetics.

[50]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.